Cargando…

Characterization of T-cell responses against IκBα in cancer patients

The nuclear factor κ light chain enhancer of activated B cells (NFκB) is constitutively active in most cancers, controlling multiple cellular processes including proliferation, invasion and resistance to therapy. NFκB is primarily regulated through the association with inhibitory proteins that are k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munir, Shamaila, Frøsig, Thomas Mørch, Hansen, Morten, Svane, Inge Marie, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518501/ https://www.ncbi.nlm.nih.gov/pubmed/23243592 http://dx.doi.org/10.4161/onci.21625

Ejemplares similares

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells
por: Munir, Shamaila, et al.
Publicado: (2013)

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot
por: Larsen, Stine Kiaer, et al.
Publicado: (2012)

Natural CD4(+) T-Cell Responses against Indoleamine 2,3-Dioxygenase
por: Munir, Shamaila, et al.
Publicado: (2012)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application
por: Junker, Niels, et al.
Publicado: (2011)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2018)

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors
por: Andersen, Rikke Sick, et al.
Publicado: (2010)

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

Therapeutic Cancer Vaccines in Combination with Conventional Therapy
por: Andersen, Mads Hald, et al.
Publicado: (2010)

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
por: Sørensen, Rikke Bæk, et al.
Publicado: (2009)

Inflammation induced PD-L1-specific T cells
por: Munir, Shamaila, et al.
Publicado: (2019)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
por: Andersen, Mads Hald
Publicado: (2012)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
por: Iversen, Trine Zeeberg, et al.
Publicado: (2013)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Cancer treatment: the combination of vaccination with other therapies
por: Andersen, Mads Hald, et al.
Publicado: (2008)

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2022)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Comment on “5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity”
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Immunoprofiles of colorectal cancer from Lynch syndrome
por: Walkowska, Joanna, et al.
Publicado: (2018)

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2021)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Functional Redundancy of the Nuclear Factor κB Inhibitors IκBα and IκBβ
por: Cheng, Janet D., et al.
Publicado: (1998)

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
por: Bendtsen, Simone Kloch, et al.
Publicado: (2022)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Keeping each other in check: A reciprocal relationship between cytokines and miRNA
por: Andersen, Mads Hald
Publicado: (2013)

FOXP3-specific immunity
por: Andersen, Mads Hald
Publicado: (2013)

T-cell dependent immunoselection
por: Andersen, Mads Hald
Publicado: (2012)

The targeting of tumor-associated macrophages by vaccination
por: Andersen, Mads Hald
Publicado: (2019)

Novel immune modulatory vaccines targeting TGFβ
por: Andersen, Mads Hald
Publicado: (2023)

Tumor microenvironment antigens
por: Andersen, Mads Hald
Publicado: (2022)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t84ra2rqs6kdcn0pcve17ovc97